Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Thrombate infusion, Anti-thrombin III
Thrombate III · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Thrombate infusion | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Thrombate infusion | DRUG | Bolus intravenous infusion of Thrombate will be given to achieve antithrombin (AT) activity levels at 150% before the 3rd dose of Enoxaparin. The dose will be based on patient weight. |
| Placebo | DRUG | Normal Saline will be given as one time IV before the 3rd dose of Enoxaparin. The dose will be based on patient weight. |
Inclusion Criteria: * Admission to trauma service * Polytraumatic injuries OR pelvic/long bone fracture * Planned admission to trauma ICU or step-down/SIMU setting (this includes STICU, SIMU/TIMU, BICU, and BIMU) * Informed consent obtained Exclusion Criteria: * Prisoners (defined as those direct...
Thrombate III is being studied in trauma injury to improve thromboprophylaxis and reduce the incidence of trauma-related venous thromboembolism. The Phase 2 trial enrolls adults aged 18 years and older in the United States. Thrombate III is not approved for this trauma injury use and remains investigational in this setting.
Thrombate III is developed by Grifols, S.A., which trades under the ticker GRFS. Grifols is the company sponsoring the clinical development program for Thrombate III in trauma injury, including the ongoing Phase 2 study of the drug in patients at risk of trauma-related venous thromboembolism.
Thrombate III is in Phase 2 development for trauma injury. The single registered trial, NCT05794165, is a Phase 2 study that is currently enrolling by invitation. No completed trials of Thrombate III for this indication are listed, so the asset remains in clinical development rather than approved for trauma injury.
Thrombate III is being evaluated in NCT05794165, titled Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism. This Phase 2 trial is enrolling by invitation, is randomized, double blind, and placebo controlled, and plans to enroll 314 participants aged 18 years and older in the United States.
Yes, Thrombate infusion is another name for Thrombate III. Both names refer to the same Grifols, S.A. product being studied in the Phase 2 NCT05794165 trial for trauma injury, where the goal is to improve thromboprophylaxis and reduce trauma-related venous thromboembolism.
Thrombate III is not approved for trauma injury. It is an investigational therapy in Phase 2 clinical development for that indication, studied in the enrolling-by-invitation trial NCT05794165. The trial is randomized, double blind, and placebo controlled, with a planned enrollment of 314 adults aged 18 years and older.